LOGIN
Phase 3 Trial Of A Single Lorecivivint Injection For Symptomatic Knee Osteoarthritis
July 2025
Phase 3 Trial Of A Single Lorecivivint Injection For Symptomatic Knee Osteoarthritis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Clin Exp Rheumatol . 2025 May;43(5):847-853.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Four hundred ninety-eight patients with moderate to severe symptomatic knee osteoarthritis were randomized to receive either a single intra-articular injection of lorecivivint 0.07 mg (n=243) or placebo (n=253). The primary outcome of interest was the change in Pain Numeric Rating Scale (NRS) at Week 12. Secondary outcomes included changes in WOMAC Function and Pain subscores, Patient Global Asses...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.